U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07496229) titled 'Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)' on March 16.

Brief Summary: This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: ...